NASDAQ:ATRA

Atara Biotherapeutics Stock Forecast, Price & News

$13.70
-0.07 (-0.51 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.29
Now: $13.70
$14.00
50-Day Range
$13.77
MA: $15.64
$17.88
52-Week Range
$7.45
Now: $13.70
$28.20
Volume627,823 shs
Average Volume876,643 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.65
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930
Employees429
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.37 per share

Profitability

Net Income$-290,980,000.00

Miscellaneous

Market Cap$1.15 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Atara Biotherapeutics Becomes Oversold (ATRA)
March 26, 2021 |  nasdaq.com
ATRA Feb 2021 15.000 put
February 11, 2021 |  au.finance.yahoo.com
ATRA Feb 2021 35.000 call
February 11, 2021 |  au.finance.yahoo.com
ATRA Feb 2021 20.000 call
January 28, 2021 |  uk.finance.yahoo.com
ATRA Feb 2021 17.500 put
January 27, 2021 |  uk.finance.yahoo.com
ATRA Feb 2021 22.500 put
January 27, 2021 |  uk.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

721st out of 2,016 stocks

Biological Products, Except Diagnostic Industry

100th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$13.70
-0.07 (-0.51 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

Is Atara Biotherapeutics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Atara Biotherapeutics?

Wall Street analysts have given Atara Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atara Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Atara Biotherapeutics
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its earnings results on Sunday, February, 28th. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.22.
View Atara Biotherapeutics' earnings history
.

How has Atara Biotherapeutics' stock been impacted by COVID-19?

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRA shares have increased by 37.6% and is now trading at $13.70.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ATRA?

10 Wall Street analysts have issued 12-month price targets for Atara Biotherapeutics' shares. Their forecasts range from $23.00 to $78.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $35.88 in the next year. This suggests a possible upside of 161.9% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:
  • Dr. Pascal Touchon D.V.M., Pres, CEO & Director (Age 58, Pay $953.88k)
  • Mr. Utpal Koppikar, Chief Financial Officer (Age 50, Pay $596.38k)
  • Mr. Joseph Newell, Exec. VP & COO (Age 51, Pay $546.1k)
  • Eric Hyllengren, Head of Investor Relations & Fin.
  • Mr. Amar Murugan, Sr. VP & Gen. Counsel (Age 46)
  • Kerry Beth Daly, Head of Corp. Communications
  • Mr. Steve Bertram, Sr. VP & Chief People Officer
  • Dr. Manher Joshi, Chief Medical Officer
  • Dr. José Eduardo Vidal Ph.D., Head of Quality Assurance and Process Sciences
  • Mr. Tim Valko, Sr. VP of Global Manufacturing & Supply Chain

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Atara Biotherapeutics stock include Eric Dobmeier, Isaac E Ciechanover, Joe Newell, Pascal Touchon and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics
.

Which major investors are buying Atara Biotherapeutics stock?

ATRA stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Atara Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $13.70.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics has a market capitalization of $1.15 billion. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

Atara Biotherapeutics employs 429 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

Where are Atara Biotherapeutics' headquarters?

Atara Biotherapeutics is headquartered at 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.